article Open AccessTop 10% cited
The Promotion and Marketing of OxyContin: Commercial Triumph, Public Health Tragedy
American Journal of Public Health · 2008 · Vol. 99(2) · pp. 221–227
Abstract
I focus on issues surrounding the promotion and marketing of controlled drugs and their regulatory oversight. Compared with noncontrolled drugs, controlled drugs, with their potential for abuse and diversion, pose different public health risks when they are overpromoted and highly prescribed. An in-depth analysis of the promotion and marketing of OxyContin illustrates some of the associated issues. Modifications of the promotion and marketing of controlled drugs by the pharmaceutical industry and an enhanced capacity of the Food and Drug Administration to regulate and monitor such promotion can have a positive impact on the public health.
Pharmaceutical industry and healthcarePharmaceutical Economics and PolicyHealth Systems, Economic Evaluations, Quality of LifePromotion (chess)Food and drug administrationPublic healthMedicineMarketingHealth promotionBusinessEnvironmental healthPublic relationsPolitical science
MeSH terms
Analgesics, OpioidCommerceDrug IndustryHumansOxycodonePersuasive CommunicationPublic HealthUnited StatesUnited States Food and Drug AdministrationSubstance-Related DisordersMarketing
Citations
884
FWCI
11.24
field-weighted impact
References
50
Percentile
98%
vs. same field & year
Citations per year
References
Major increases in opioid analgesic abuse in the United States: Concerns and strategies
Drug and Alcohol Dependence · 2005 · 837 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.